MDx/CDx Focus: CHMP Recommends Mekinist; Biocept Launches Biomarker Research Services for Pharma | GenomeWeb

UK's CHMP Grants Positive Review of MEK Inhibitor Melanoma Drug Mekinist

The UK's Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission grant marketing authorization to GlaxoSmithKline's Mekinist (trametinib).

"The CHMP, on the basis of quality, safety and efficacy data submitted, considers there to be a favourable benefit-to-risk balance for Mekinist and therefore recommends the granting of the marketing authorization," the committee said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.